Jaimin Shah is a patent litigator, with experience in a variety of technologies such as pharmaceuticals, medical devices, smartphone messaging apps, digital data compression systems, oil drilling, fire-resistant glass flooring, and packaging machinery.
Jaimin has experience in all phases of patent litigation. Whether taking a deposition or writing an appellate brief, he goes above and beyond to ensure each task ultimately makes a significant inroad in the case. Jaimin brings boundless energy, creativity, and perseverance to each matter in which he is involved.
Some of Jaimin's achievements include:
- Represented a Canadian pharmaceutical company in a patent litigation involving the Gaucher Disease drug Cerdelga®, developing a robust invalidity case for trial (including deposing the key inventors). The case settled favorably for the client on the eve of trial.
- Represented a packaging company in a contentious and protracted patent litigation involving automatic cotton bale packaging and sampling systems, resulting in a settlement after fact discovery, claim construction, and briefing on a dispositive motion.
- Represented a fire-rated glass flooring system designer and developer in a patent litigation, including arguing and winning a motion to amend the pleadings to add Lanham Act claims in the case.
- Represented an Indian pharmaceutical company in a patent litigation involving a breast cancer diagnostic dye isosulfan blue, resulting in the reversal of the district court’s analysis on a preliminary injunction for two of the three asserted patents (and subsequent settlement).
- Represented an Indian pharmaceutical company in a patent litigation involving a schizophrenia drug, developing robust expert testimony on noninfringement, which resulted in voluntary dismissal of the case.
He has also represented clients in inter partes review and other post-grant proceedings before the Patent Trial and Appeal Board (PTAB).
Jaimin brings depth and maturity to his litigation practice due, in part, to his in-house experience, where he gained first-hand knowledge in litigation strategy and the business realities that inform company decisions.
Jaimin served as a judicial extern for the Hon. James F. Holderman and the Hon. Virginia M. Kendall in the U.S. District Court for the Northern District of Illinois. That experience enabled him to build a “behind the bench” perspective on how judges decide cases.
Jaimin has a strong technical background in biochemistry and biotechnology. He has a Master of Science degree in Biotechnology from the Indian Institute of Technology-Bombay. His J.D. is from the UIC John Marshall Law School, cum laude, where he received the CALI award in Professional Responsibility and International Law.
As part of his effort to pay it forward, Jaimin represented a middle school student in a contentious expulsion matter. He conducted an evidentiary hearing in front of the Board of Education, which resulted in a settlement under which terms the student was able to return to school and graduate.
Honoree, Illinois Super Lawyers "Rising Stars" (2021)
Honoree, Best Lawyers® "Ones to Watch", Litigation - Patent (2022)
All Service Areas
- University of Illinois Chicago School of Law (2016)
- Indian Institute of Technology, Bombay (2004)
- St. Xavier's College, Ahmedabad (2001)
- State - Illinois
- Federal - Northern District of Illinois
- Federal - District of Colorado
Speeches and Publications
- "Competitive Generic Therapy Exclusivity," 8th Annual Pharma IPR Conference, Mumbai, India (March 6, 2019)
- "Third Circuit Recognizes Catch-22 Situation in Pleading Trade Secret Misappropriation," Taft Law Bulletin (June 16, 2021)
- “Structural Obviousness Receives a Boost at the Federal Circuit,” (co-author with Aaron Johnson), Taft Law Bulletin (Apr. 23, 2020)
- "For Now, Competitive Generic Therapy Exclusivity is a Mirage," (co-author with Stephen Auten and Sinchan Shah), Law360 (Feb. 26, 2019)
- Evidence in Patent Cases, ch.12 (Kenneth L. Dorsney et al. eds., 1st ed. 2018) (co-author)
- "Must Whole Patent Be Nixed To Forfeit 180-Day Exclusivity?," (co-author with Steve Auten) Law360 (July 25, 2018)
- "Pulling the ‘Trigger’ on the Hatch-Waxman Act's 180-Day Exclusivity Using Inter Partes Review," The John Marshall Review of Intellectual Property Law (May 2015)
- "Effects of pH and Ionic Strength on the Assembly and Bundling of FtsZ Protofilaments: A Possible Role of Electrostatic Interactions in the Bundling of Protofilaments," (co-author) International Journal of Biological Macromolecules (2006)
- Intellectual Property Law Association of Chicago
Co-chair, CLE Committee